Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score

• Main Authors: Jochen G. Mainz (Author), Carlos Zagoya (Author), Louise Polte (Author), Lutz Naehrlich (Author), Lenny Sasse (Author), Olaf Eickmeier (Author), Christina Smaczny (Author), Anton Barucha (Author), Lilith Bechinger (Author), Franziska Duckstein (Author), Ludwik Kurzidim (Author), Patience Eschenhagen (Author), Laura Caley (Author), Daniel Peckham (Author), Carsten Schwarz (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: The novel and highly effective CFTR modulator combination of elexacaftor-tezacaftor-ivacaftor (ETI) has been shown to improve lung function and body weight in people with Cystic Fibrosis (pwCF) carrying a F508del mutation. However, the impact of these modulators on gastrointestinal (GI)...